{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:46Z","timestamp":1790082946364,"version":"4.0.1"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 012066"],"award-info":[{"award-number":["ZIA BC 012066"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["ZIA BC 012066"],"award-info":[{"award-number":["ZIA BC 012066"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029695","name":"Children's Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029695","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors. Especially in the pediatric population, pre- and post-treatment biopsies are rarely performed due to ethical reasons, and thus, our understanding is still very limited regarding the mechanisms in the tumor microenvironment by which tumor cells exclude effectors and attract immune-suppressive cells. Nevertheless, based on the principles that are known, current T-cell engineering has leveraged some of these processes and created more potent CAR T-cells. The recent discovery of new oncofetal antigens and progress made in CAR design have expanded the potential pool of candidate antigens for therapeutic development. The most promising approaches to enhance CAR T-cells are novel CAR gating strategies, creative ways of cytokine delivery to the TME without enhancing systemic toxicity, and hijacking the chemokine axis of tumors for migratory purposes. With these new modifications, the next step in the era of CAR T-cell development will be the clinical validation of these promising preclinical findings.<\/jats:p>","DOI":"10.1007\/s10555-024-10214-6","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:01:49Z","timestamp":1727215309000},"page":"1445-1461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR T-cells for pediatric solid tumors: where to go from here?"],"prefix":"10.1007","volume":"43","author":[{"given":"Tina","family":"Trautmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Yakobian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"10","key":"10214_CR1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma, M., Obergfell, K., Topp, S., Panier, V., & Wu, J. (2023). The next-generation CAR-T therapy landscape. Nature Reviews. Drug Discovery, 22(10), 776\u2013777. https:\/\/doi.org\/10.1038\/d41573-023-00140-7","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"26","key":"10214_CR2","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017\u20134023. https:\/\/doi.org\/10.1182\/blood-2014-12-580068","journal-title":"Blood"},{"issue":"16","key":"10214_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10214_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10214_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews Clinical Oncology, 20(6), 359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7","key":"10214_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J., Lymphoma Program Investigators at the University of, P. (2021). Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. New England Journal of Medicine, 384(7), 673\u2013674. https:\/\/doi.org\/10.1056\/NEJMc2030164","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10214_CR7","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., et al. (2021). Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 124(11), 1759\u20131776. https:\/\/doi.org\/10.1038\/s41416-021-01353-6","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10214_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), 64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169","journal-title":"New England Journal of Medicine"},{"issue":"7949","key":"10214_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L., & Mackall, C. L. (2023). CAR immune cells: Design principles, resistance and the next generation. Nature, 614(7949), 635\u2013648. https:\/\/doi.org\/10.1038\/s41586-023-05707-3","journal-title":"Nature"},{"issue":"9","key":"10214_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G., & Mackall, C. L. (2019). Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 25(9), 1341\u20131355. https:\/\/doi.org\/10.1038\/s41591-019-0564-6","journal-title":"Nature Medicine"},{"issue":"7655","key":"10214_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Riviere, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423\u2013431. https:\/\/doi.org\/10.1038\/nature22395","journal-title":"Nature"},{"issue":"3","key":"10214_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17(3), 147\u2013167. https:\/\/doi.org\/10.1038\/s41571-019-0297-y","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"11","key":"10214_CR13","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020). CAR T cell therapy for solid tumors: Bright future or dark reality? Molecular Therapy, 28(11), 2320\u20132339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015","journal-title":"Molecular Therapy"},{"key":"10214_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002555","author":"DG Tantalo","year":"2021","unstructured":"Tantalo, D. G., Oliver, A. J., von Scheidt, B., Harrison, A. J., Mueller, S. N., Kershaw, M. H., et al. (2021). Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002555","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10214_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041171","author":"J Maher","year":"2023","unstructured":"Maher, J., & Davies, D. M. (2023). CAR-based immunotherapy of solid tumours-A survey of the emerging targets. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15041171","journal-title":"Cancers (Basel)"},{"key":"10214_CR16","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber, D., & Wang, L. D. (2022). Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. eBioMedicine, 77, 103941. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103941","journal-title":"eBioMedicine"},{"issue":"14","key":"10214_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., et al. (2023). GD2-CART01 for relapsed or refractory high-risk neuroblastoma. New England Journal of Medicine, 388(14), 1284\u20131295. https:\/\/doi.org\/10.1056\/NEJMoa2210859","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10214_CR18","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., et al. (2017). CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Molecular Therapy, 25(9), 2214\u20132224. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.012","journal-title":"Molecular Therapy"},{"issue":"1","key":"10214_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C. F., Duault, C., Subrahmanyam, P. B., et al. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell, 42(1), 35\u201351. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.011. e38.","journal-title":"Cancer Cell"},{"issue":"23","key":"10214_CR20","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 118(23), 6050\u20136056. https:\/\/doi.org\/10.1182\/blood-2011-05-354449","journal-title":"Blood"},{"issue":"11","key":"10214_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14(11), 1264\u20131270. https:\/\/doi.org\/10.1038\/nm.1882","journal-title":"Nature Medicine"},{"key":"10214_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6169","author":"K Straathof","year":"2020","unstructured":"Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., et al. (2020). Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.abd6169","journal-title":"Science Translational Medicine"},{"key":"10214_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., et al. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"5","key":"10214_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019). Pharmacologic control of CAR-T cell function using dasatinib. Blood Advances, 3(5), 711\u2013717. https:\/\/doi.org\/10.1182\/bloodadvances.2018028720","journal-title":"Blood Advances"},{"issue":"12_Supplement","key":"10214_CR25","doi-asserted-by":"publisher","first-page":"CT001-CT001","DOI":"10.1158\/1538-7445.Am2022-ct001","volume":"82","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., et al. (2022). Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells. Cancer Research, 82(12_Supplement), CT001\u2013CT001. https:\/\/doi.org\/10.1158\/1538-7445.Am2022-ct001","journal-title":"Cancer Research"},{"issue":"5","key":"10214_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus\u2013induced lymphoma in allogeneic transplant recipients. Blood, 92(5), 1549\u20131555. https:\/\/doi.org\/10.1182\/blood.V92.5.1549","journal-title":"Blood"},{"issue":"3","key":"10214_CR27","doi-asserted-by":"publisher","first-page":"e0152196","DOI":"10.1371\/journal.pone.0152196","volume":"11","author":"S Thomas","year":"2016","unstructured":"Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One1, 11(3), e0152196. https:\/\/doi.org\/10.1371\/journal.pone.0152196","journal-title":"PLoS One1"},{"issue":"10","key":"10214_CR28","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","volume":"148","author":"L Yu","year":"2022","unstructured":"Yu, L., Huang, L., Lin, D., Lai, X., Wu, L., Liao, X., et al. (2022). GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients. Journal of Cancer Research and Clinical Oncology, 148(10), 2643\u20132652. https:\/\/doi.org\/10.1007\/s00432-021-03839-5","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"6","key":"10214_CR29","doi-asserted-by":"publisher","first-page":"e1433518","DOI":"10.1080\/2162402x.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., et al. (2018). Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology, 7(6), e1433518. https:\/\/doi.org\/10.1080\/2162402x.2018.1433518","journal-title":"Oncoimmunology"},{"issue":"13_Supplement","key":"10214_CR30","doi-asserted-by":"publisher","first-page":"LB-147-LB-147","DOI":"10.1158\/1538-7445.Am2019-lb-147","volume":"79","author":"SA Navai","year":"2019","unstructured":"Navai, S. A., Derenzo, C., Joseph, S., Sanber, K., Byrd, T., Zhang, H., et al. (2019). Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas. Cancer Research, 79(13_Supplement), LB-147-LB-147. https:\/\/doi.org\/10.1158\/1538-7445.Am2019-lb-147","journal-title":"Cancer Research"},{"issue":"3","key":"10214_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cgt.2011.83","volume":"19","author":"N Rainusso","year":"2012","unstructured":"Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., et al. (2012). Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Therapy, 19(3), 212\u2013217. https:\/\/doi.org\/10.1038\/cgt.2011.83","journal-title":"Cancer Gene Therapy"},{"issue":"Suppl 2","key":"10214_CR32","doi-asserted-by":"publisher","first-page":"A418","DOI":"10.1136\/jitc-2022-SITC2022.0397","volume":"10","author":"K Sabina","year":"2022","unstructured":"Sabina, K., Sneha, R., Tara, M., Cristina, C., Ahmad, A., Norma, G., et al. (2022). 397 Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies. Journal for ImmunoTherapy of Cancer, 10(Suppl 2), A418. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0397","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"16_suppl","key":"10214_CR33","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/JCO.2022.40.16_suppl.2541","volume":"40","author":"CM Albert","year":"2022","unstructured":"Albert, C. M., Pinto, N. R., Taylor, M., Wilson, A., Rawlings-Rhea, S., Mgebroff, S., et al. (2022). STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent\/refractory solid tumors in children and young adults. Journal of Clinical Oncology, 40(16_suppl), 2541\u20132541. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2541","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10214_CR34","doi-asserted-by":"publisher","first-page":"10011-10011","DOI":"10.1200\/JCO.2022.40.16_suppl.10011","volume":"40","author":"NR Pinto","year":"2022","unstructured":"Pinto, N. R., Albert, C. M., Taylor, M., Wilson, A., Rawlings-Rhea, S., Huang, W., et al. (2022). STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed\/refractory solid tumors. Journal of Clinical Oncology, 40(16_suppl), 10011\u201310011. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.10011","journal-title":"Journal of Clinical Oncology"},{"issue":"7903","key":"10214_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., et al. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"Suppl 1","key":"10214_CR36","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/neuonc\/noac079.072","volume":"24","author":"M Monje","year":"2022","unstructured":"Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., et al. (2022). DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells. Neuro-Oncology, 24(Suppl 1), i20-21. https:\/\/doi.org\/10.1093\/neuonc\/noac079.072","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10214_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., et al. (2018). Potent antitumor efficacy of anti-GD2 CAR T cells in H3\u2013K27M(+) diffuse midline gliomas. Nature Medicine, 24(5), 572\u2013579. https:\/\/doi.org\/10.1038\/s41591-018-0006-x","journal-title":"Nature Medicine"},{"key":"10214_CR38","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","volume":"63","author":"Q Fu","year":"2023","unstructured":"Fu, Q., Zheng, Y., Fang, W., Zhao, Q., Zhao, P., Liu, L., et al. (2023). RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: A phase I trial. EClinicalMedicine, 63, 102175. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102175","journal-title":"EClinicalMedicine"},{"key":"10214_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006119","author":"J Tang","year":"2023","unstructured":"Tang, J., Sheng, J., Zhang, Q., Ji, Y., Wang, X., Zhang, J., et al. (2023). Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006119","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"48","key":"10214_CR40","doi-asserted-by":"publisher","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., et al. (2023). EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Science Advances, 9(48), eadg9721. https:\/\/doi.org\/10.1126\/sciadv.adg9721","journal-title":"Science Advances"},{"issue":"5","key":"10214_CR41","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., et al. (2017). Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Molecular Therapy, 25(5), 1248\u20131258. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.010","journal-title":"Molecular Therapy"},{"issue":"7","key":"10214_CR42","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402x.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., et al. (2018). CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology, 7(7), e1440169. https:\/\/doi.org\/10.1080\/2162402x.2018.1440169","journal-title":"Oncoimmunology"},{"issue":"26","key":"10214_CR43","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., et al. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. New England Journal of Medicine, 375(26), 2561\u20132569. https:\/\/doi.org\/10.1056\/NEJMoa1610497","journal-title":"New England Journal of Medicine"},{"key":"10214_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","author":"CE Brown","year":"2024","unstructured":"Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., et al. (2024). Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: A phase 1 trial. Nature Medicine. https:\/\/doi.org\/10.1038\/s41591-024-02875-1","journal-title":"Nature Medicine"},{"issue":"6","key":"10214_CR45","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., et al. (2022). Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nature Medicine, 28(6), 1189\u20131198. https:\/\/doi.org\/10.1038\/s41591-022-01800-8","journal-title":"Nature Medicine"},{"issue":"4","key":"10214_CR46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang, H., Shi, Z., Wang, P., Wang, C., Yang, L., Du, G., et al. (2019). Claudin18.2-Specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. Journal of the National Cancer Institute, 111(4), 409\u2013418. https:\/\/doi.org\/10.1093\/jnci\/djy134","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10214_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","volume":"16","author":"C Qi","year":"2023","unstructured":"Qi, C., Xie, T., Zhou, J., Wang, X., Gong, J., Zhang, X., et al. (2023). CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. Journal of Hematology Oncology, 16(1), 102. https:\/\/doi.org\/10.1186\/s13045-023-01491-9","journal-title":"Journal of Hematology Oncology"},{"key":"10214_CR48","doi-asserted-by":"publisher","first-page":"S620","DOI":"10.1016\/j.annonc.2023.09.2157","volume":"34","author":"C Qi","year":"2023","unstructured":"Qi, C., Chang, L., Li, J., Gong, J., Wang, X., Wang, Z., et al. (2023). 1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer. Annals of Oncology, 34, S620. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2157","journal-title":"Annals of Oncology"},{"issue":"4_Supplement","key":"10214_CR49","doi-asserted-by":"publisher","first-page":"P2\u201309\u201313-P02\u201309","DOI":"10.1158\/1538-7445.Sabcs18-p2-09-13","volume":"79","author":"J Specht","year":"2019","unstructured":"Specht, J., Lee, S., Turtle, C., Berger, C., Balakrishnan, A., Srivastava, S., et al. (2019). Abstract P2\u201309\u201313: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Research, 79(4_Supplement), P2-09-13-P02-09\u201313. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs18-p2-09-13","journal-title":"Cancer Research"},{"issue":"2","key":"10214_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S., Furlan, S. N., Jaeger-Ruckstuhl, C. A., Sarvothama, M., Berger, C., Smythe, K. S., et al. (2021). Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell, 39(2), 193-208.e110. https:\/\/doi.org\/10.1016\/j.ccell.2020.11.005","journal-title":"Cancer Cell"},{"issue":"6","key":"10214_CR51","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/1078-0432.Ccr-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo, Y., Feng, K., Liu, Y., Wu, Z., Dai, H., Yang, Q., et al. (2018). Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clinical Cancer Research, 24(6), 1277\u20131286. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0432","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10214_CR52","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., et al. (2016). Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Science China Life sciences, 59(5), 468\u2013479. https:\/\/doi.org\/10.1007\/s11427-016-5023-8","journal-title":"Science China Life sciences"},{"issue":"10","key":"10214_CR53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Guo, Y., Wu, Z., Feng, K., Tong, C., Wang, Y., et al. (2020). Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy, 22(10), 573\u2013580. https:\/\/doi.org\/10.1016\/j.jcyt.2020.04.088","journal-title":"Cytotherapy"},{"issue":"5","key":"10214_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019). Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell, 36(5), 471\u2013482. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006","journal-title":"Cancer Cell"},{"issue":"11","key":"10214_CR55","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.Cd-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S., Zauderer, M. G., Rivi\u00e8re, I., Solomon, S. B., Rusch, V. W., O\u2019Cearbhaill, R. E., et al. (2021). A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discovery, 11(11), 2748\u20132763. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0407","journal-title":"Cancer Discovery"},{"issue":"4","key":"10214_CR56","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V., Barber-Rotenberg, J. S., Jung, I. Y., Lacey, S. F., Rech, A. J., Davis, M. M., et al. (2022). PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial. Nature Medicine, 28(4), 724\u2013734. https:\/\/doi.org\/10.1038\/s41591-022-01726-1","journal-title":"Nature Medicine"},{"issue":"2","key":"10214_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.Ccr-21-3798","volume":"29","author":"W Brochier","year":"2023","unstructured":"Brochier, W., Bricard, O., & Coulie, P. G. (2023). Facts and hopes in cancer antigens recognized by T cells. Clinical Cancer Research, 29(2), 309\u2013315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3798","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10214_CR58","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V., & Rosenberg, S. A. (2020). Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell, 38(4), 454\u2013472. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.013","journal-title":"Cancer Cell"},{"key":"10214_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/edbk_200773","volume":"38","author":"C DeRenzo","year":"2018","unstructured":"DeRenzo, C., Krenciute, G., & Gottschalk, S. (2018). The landscape of CAR T cells beyond acute lymphoblastic leukemia for pediatric solid tumors. American Society of Clinical Oncology Educational Book, 38, 830\u2013837. https:\/\/doi.org\/10.1200\/edbk_200773","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10214_CR60","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/mto.2016.6","volume":"3","author":"K Newick","year":"2016","unstructured":"Newick, K., Moon, E., & Albelda, S. M. (2016). Chimeric antigen receptor T-cell therapy for solid tumors. Molecular Therapy Oncolytics, 3, 16006. https:\/\/doi.org\/10.1038\/mto.2016.6","journal-title":"Molecular Therapy Oncolytics"},{"issue":"26","key":"10214_CR61","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., et al. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10214_CR62","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, O., et al. (2017). Chimeric antigen receptor T cells in refractory B-cell lymphomas. New England Journal of Medicine, 377(26), 2545\u20132554. https:\/\/doi.org\/10.1056\/NEJMoa1708566","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10214_CR63","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., et al. (2020). Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell, 183(1), 126\u2013142. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022. e117.","journal-title":"Cell"},{"issue":"5","key":"10214_CR64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3892\/ijo.3.5.909","volume":"3","author":"G Lammie","year":"1993","unstructured":"Lammie, G., Cheung, N., Gerald, W., Rosenblum, M., & Cordoncardo, C. (1993). Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - An immunohistochemical study. International Journal of Oncology, 3(5), 909\u2013915. https:\/\/doi.org\/10.3892\/ijo.3.5.909","journal-title":"International Journal of Oncology"},{"issue":"11","key":"10214_CR65","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey, A., Courtney, A. N., Montalbano, A., Robinson, S., Liu, K., Li, M., et al. (2020). Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: An interim analysis. Nature Medicine, 26(11), 1686\u20131690. https:\/\/doi.org\/10.1038\/s41591-020-1074-2","journal-title":"Nature Medicine"},{"issue":"4","key":"10214_CR66","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., et al. (2023). Tumor inflammation-associated neurotoxicity. Nature Medicine, 29(4), 803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","journal-title":"Nature Medicine"},{"issue":"1","key":"10214_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., et al. (2018). High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunology Research, 6(1), 36\u201346. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0211","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"10214_CR68","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/2326-6066.CIR-18-0089","volume":"6","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G., Weber, E. W., Lynn, R. C., Xu, P., & Mackall, C. L. (2018). Neurotoxicity associated with a high-affinity GD2 CAR-letter. Cancer Immunology Research, 6(4), 494\u2013495. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0089","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10214_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder, S., Bosse, K. R., Zhu, Z., Zhelev, D., Majzner, R. G., Radosevich, M. T., et al. (2022). GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell, 40(1), 53-69.e59. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.005","journal-title":"Cancer Cell"},{"issue":"1","key":"10214_CR70","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1038\/s41467-024-47649-y","volume":"15","author":"TI Shaw","year":"2024","unstructured":"Shaw, T. I., Wagner, J., Tian, L., Wickman, E., Poudel, S., Wang, J., et al. (2024). Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression. Nature Communications, 15(1), 3732. https:\/\/doi.org\/10.1038\/s41467-024-47649-y","journal-title":"Nature Communications"},{"issue":"4","key":"10214_CR71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1042\/EBC20220025","volume":"66","author":"Q Yan","year":"2022","unstructured":"Yan, Q., Fang, X., Li, C., Lan, P., & Guan, X. (2022). Oncofetal proteins and cancer stem cells. Essays in Biochemistry, 66(4), 423\u2013433. https:\/\/doi.org\/10.1042\/EBC20220025","journal-title":"Essays in Biochemistry"},{"issue":"3","key":"10214_CR72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccell.2017.08.003","volume":"32","author":"KR Bosse","year":"2017","unstructured":"Bosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., et al. (2017). Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell, 32(3), 295\u2013309. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.003. e212.","journal-title":"Cancer Cell"},{"issue":"32","key":"10214_CR73","doi-asserted-by":"publisher","first-page":"E6623","DOI":"10.1073\/pnas.1706055114","volume":"114","author":"N Li","year":"2017","unstructured":"Li, N., Fu, H., Hewitt, S. M., Dimitrov, D. S., & Ho, M. (2017). Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proceedings of the National Academy of Sciences USA, 114(32), E6623\u2013E6631. https:\/\/doi.org\/10.1073\/pnas.1706055114","journal-title":"Proceedings of the National Academy of Sciences USA"},{"issue":"6","key":"10214_CR74","doi-asserted-by":"publisher","first-page":"100297","DOI":"10.1016\/j.xcrm.2021.100297","volume":"2","author":"N Li","year":"2021","unstructured":"Li, N., Torres, M. B., Spetz, M. R., Wang, R., Peng, L., Tian, M., et al. (2021). CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Rep Med, 2(6), 100297. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100297","journal-title":"Cell Rep Med"},{"key":"10214_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004450","author":"JB Foster","year":"2022","unstructured":"Foster, J. B., Griffin, C., Rokita, J. L., Stern, A., Brimley, C., Rathi, K., et al. (2022). Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004450","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10214_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005881","author":"M Sun","year":"2023","unstructured":"Sun, M., Cao, Y., Okada, R., Reyes-Gonzalez, J. M., Stack, H. G., Qin, H., et al. (2023). Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005881","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10214_CR77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155621","author":"M Tian","year":"2022","unstructured":"Tian, M., Cheuk, A. T., Wei, J. S., Abdelmaksoud, A., Chou, H. C., Milewski, D., et al. (2022). An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. The Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI155621","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10214_CR78","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., et al. (2015). 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine, 21(6), 581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nature Medicine"},{"issue":"6625","key":"10214_CR79","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M., Frankel, N. W., Reddy, N. R., Bhargava, H. K., Yoshida, M. A., Stark, S. R., et al. (2022). Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science, 378(6625), 1624. https:\/\/doi.org\/10.1126\/science.aba1624. eaba1624.","journal-title":"Science"},{"issue":"591","key":"10214_CR80","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J. M., Alavi, J., Perry, N., et al. (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Science Translational Medicine, 13(591), 8836.","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10214_CR81","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L., Bassiri, H., et al. (2021). Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature Communications, 12(1), 511. https:\/\/doi.org\/10.1038\/s41467-020-20785-x","journal-title":"Nature Communications"},{"issue":"4","key":"10214_CR82","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., et al. (2016). Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell, 164(4), 780\u2013791. https:\/\/doi.org\/10.1016\/j.cell.2016.01.012","journal-title":"Cell"},{"issue":"2","key":"10214_CR83","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., et al. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167(2), 419\u2013432. https:\/\/doi.org\/10.1016\/j.cell.2016.09.011. e416.","journal-title":"Cell"},{"issue":"3","key":"10214_CR84","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., et al. (2019). Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell, 35(3), 489\u2013503. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.003. e488.","journal-title":"Cancer Cell"},{"issue":"7952","key":"10214_CR85","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W. J., Lareau, C., et al. (2023). Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 615(7952), 507\u2013516. https:\/\/doi.org\/10.1038\/s41586-023-05778-2","journal-title":"Nature"},{"issue":"215","key":"10214_CR86","doi-asserted-by":"publisher","first-page":"215ra172\u2013215ra1","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M., & Sadelain, M. (2013). PD-1\u2013and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5(215), 215ra172-215ra172.","journal-title":"Science Translational Medicine"},{"issue":"215","key":"10214_CR87","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M., & Sadelain, M. (2013). PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5(215), 215ra172. https:\/\/doi.org\/10.1126\/scitranslmed.3006597","journal-title":"Science Translational Medicine"},{"key":"10214_CR88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015795","author":"H Shalabi","year":"2022","unstructured":"Shalabi, H., Qin, H., Su, A., Yates, B., Wolters, P. L., Steinberg, S. M., et al. (2022). CD19\/22 CAR T-cells in children and young adults with B-ALL: Phase I results and development of a novel bicistronic CAR. Blood. https:\/\/doi.org\/10.1182\/blood.2022015795","journal-title":"Blood"},{"issue":"8","key":"10214_CR89","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C., Anderson, L. D., Jr, Shah, N., Madduri, D., Berdeja, J., Lonial, S., et al. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10214_CR90","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","volume":"114","author":"JM Foran","year":"2001","unstructured":"Foran, J. M., Norton, A. J., Micallef, I. N., Taussig, D. C., Amess, J. A., Rohatiner, A. Z., et al. (2001). Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis. British Journal of Haematology, 114(4), 881\u2013883. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03019.x","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10214_CR91","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1002\/art.34560","volume":"64","author":"JD Jones","year":"2012","unstructured":"Jones, J. D., Hamilton, B. J., & Rigby, W. F. (2012). Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis and Rheumatism, 64(10), 3111\u20133118. https:\/\/doi.org\/10.1002\/art.34560","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10214_CR92","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/1096-911X(20010101)36:1<194::AID-MPO1046>3.0.CO;2-B","volume":"36","author":"K Kramer","year":"2001","unstructured":"Kramer, K., Gerald, W. L., Kushner, B. H., Larson, S. M., Hameed, M., & Cheung, N. K. (2001). Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Medical and Pediatric Oncology, 36(1), 194\u2013196. https:\/\/doi.org\/10.1002\/1096-911X(20010101)36:1<194::AID-MPO1046>3.0.CO;2-B","journal-title":"Medical and Pediatric Oncology"},{"issue":"10","key":"10214_CR93","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G., & Mackall, C. L. (2018). Tumor antigen escape from CAR T-cell therapy. Cancer Discovery, 8(10), 1219\u20131226. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442","journal-title":"Cancer Discovery"},{"key":"10214_CR94","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad, N., Wang, R., Li, W., Zhang, Z., Chang, Y., Hu, Y., et al. (2022). A novel TanCAR targeting IL13Ralpha2 and EphA2 for enhanced glioblastoma therapy. Molecular Therapy Oncolytics, 24, 729\u2013741. https:\/\/doi.org\/10.1016\/j.omto.2022.02.012","journal-title":"Molecular Therapy Oncolytics"},{"issue":"20","key":"10214_CR95","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood.2022018598","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie, C., Lekakis, L. J., Marzolini, M. A. V., Ramakrishnan, A., Zhang, Y., Hu, Y., et al. (2023). Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood, 141(20), 2470\u20132482. https:\/\/doi.org\/10.1182\/blood.2022018598","journal-title":"Blood"},{"key":"10214_CR96","doi-asserted-by":"publisher","first-page":"114358","DOI":"10.1016\/j.addr.2022.114358","volume":"187","author":"AC McCue","year":"2022","unstructured":"McCue, A. C., Yao, Z., & Kuhlman, B. (2022). Advances in modular control of CAR-T therapy with adapter-mediated CARs. Advanced Drug Delivery Reviews, 187, 114358. https:\/\/doi.org\/10.1016\/j.addr.2022.114358","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"6667","key":"10214_CR97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.add7034","volume":"382","author":"RL Vincent","year":"2023","unstructured":"Vincent, R. L., Gurbatri, C. R., Li, F., Vardoshvili, A., Coker, C., Im, J., et al. (2023). Probiotic-guided CAR-T cells for solid tumor targeting. Science, 382(6667), 211\u2013218. https:\/\/doi.org\/10.1126\/science.add7034","journal-title":"Science"},{"issue":"1","key":"10214_CR98","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1038\/s41467-023-41518-w","volume":"14","author":"S Mayer","year":"2023","unstructured":"Mayer, S., Milo, T., Isaacson, A., Halperin, C., Miyara, S., Stein, Y., et al. (2023). The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. Nature Communications, 14(1), 5810. https:\/\/doi.org\/10.1038\/s41467-023-41518-w","journal-title":"Nature Communications"},{"issue":"16","key":"10214_CR99","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M., & Simon, M. C. (2020). The tumor microenvironment. Current Biology, 30(16), R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Current Biology"},{"issue":"5","key":"10214_CR100","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu, G., Rui, W., Zhao, X., & Lin, X. (2021). Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cellular & Molecular Immunology, 18(5), 1085\u20131095. https:\/\/doi.org\/10.1038\/s41423-021-00655-2","journal-title":"Cellular & Molecular Immunology"},{"key":"10214_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136995","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier, A. J., & Elsawa, S. F. (2021). Macrophage polarization states in the tumor microenvironment. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms22136995","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10214_CR102","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. The Journal of Pathology, 214(2), 199\u2013210. https:\/\/doi.org\/10.1002\/path.2277","journal-title":"The Journal of Pathology"},{"issue":"11","key":"10214_CR103","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394","journal-title":"Nature Medicine"},{"issue":"6","key":"10214_CR104","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K., & Nishikawa, H. (2019). Regulatory T cells in cancer immunosuppression - Implications for anticancer therapy. Nature Reviews Clinical Oncology, 16(6), 356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"10","key":"10214_CR105","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1084\/jem.20101956","volume":"208","author":"B Molon","year":"2011","unstructured":"Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., et al. (2011). Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. Journal of Experimental Medicine, 208(10), 1949\u20131962. https:\/\/doi.org\/10.1084\/jem.20101956","journal-title":"Journal of Experimental Medicine"},{"issue":"82","key":"10214_CR106","doi-asserted-by":"publisher","first-page":"eabq3016","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng, J. J., Wang, L., Li, Z., Ku, C. L., & Ho, P. C. (2023). Metabolic challenges and interventions in CAR T cell therapy. Science Immunology, 8(82), eabq3016. https:\/\/doi.org\/10.1126\/sciimmunol.abq3016","journal-title":"Science Immunology"},{"issue":"12","key":"10214_CR107","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/2326-6066.CIR-20-0837","volume":"9","author":"C Kantari-Mimoun","year":"2021","unstructured":"Kantari-Mimoun, C., Barrin, S., Vimeux, L., Haghiri, S., Gervais, C., Joaquina, S., et al. (2021). CAR T-cell entry into tumor islets is a two-step process dependent on IFNgamma and ICAM-1. Cancer Immunology Research, 9(12), 1425\u20131438. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0837","journal-title":"Cancer Immunology Research"},{"issue":"11","key":"10214_CR108","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun, R., Sun, Y., Wu, C., Liu, Y., Zhou, M., Dong, Y., et al. (2023). CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-kappaB\/SDF-1alpha axis to enhance efficacy against pancreatic cancer. Molecular Therapy, 31(11), 3193\u20133209. https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.010","journal-title":"Molecular Therapy"},{"issue":"6","key":"10214_CR109","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J., Hanafi, L. A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., et al. (2016). CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. The Journal of Clinical Investigation, 126(6), 2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309","journal-title":"The Journal of Clinical Investigation"},{"issue":"7","key":"10214_CR110","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.194.7.953","volume":"194","author":"W Weninger","year":"2001","unstructured":"Weninger, W., Crowley, M. A., Manjunath, N., & von Andrian, U. H. (2001). Migratory properties of naive, effector, and memory CD8(+) T cells. Journal of Experimental Medicine, 194(7), 953\u2013966. https:\/\/doi.org\/10.1084\/jem.194.7.953","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10214_CR111","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.4110\/in.2020.20.e20","volume":"20","author":"H Choi","year":"2020","unstructured":"Choi, H., Song, H., & Jung, Y. W. (2020). The roles of CCR7 for the homing of memory CD8+ T cells into their survival niches. Immune Network, 20(3), e20. https:\/\/doi.org\/10.4110\/in.2020.20.e20","journal-title":"Immune Network"},{"issue":"1","key":"10214_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. (2024). CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn. Nature Reviews Clinical Oncology, 21(1), 47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"12","key":"10214_CR113","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., et al. (2017). Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research, 5(12), 1152\u20131161. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189","journal-title":"Cancer Immunology Research"},{"issue":"9","key":"10214_CR114","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., K\u00fcnkele, A., et al. (2021). Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: An interim analysis. Nature Medicine, 27(9), 1544\u20131552. https:\/\/doi.org\/10.1038\/s41591-021-01404-8","journal-title":"Nature Medicine"},{"issue":"2","key":"10214_CR115","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1200\/JCO.1989.7.2.250","volume":"7","author":"B Fisher","year":"1989","unstructured":"Fisher, B., Packard, B. S., Read, E. J., Carrasquillo, J. A., Carter, C. S., Topalian, S. L., et al. (1989). Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. Journal of Clinical Oncology, 7(2), 250\u2013261. https:\/\/doi.org\/10.1200\/JCO.1989.7.2.250","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10214_CR116","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/jnci\/81.22.1709","volume":"81","author":"KD Griffith","year":"1989","unstructured":"Griffith, K. D., Read, E. J., Carrasquillo, J. A., Carter, C. S., Yang, J. C., Fisher, B., et al. (1989). In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. Journal of the National Cancer Institute, 81(22), 1709\u20131717. https:\/\/doi.org\/10.1093\/jnci\/81.22.1709","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10214_CR117","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ncponc1278","volume":"6","author":"SS Yaghoubi","year":"2009","unstructured":"Yaghoubi, S. S., Jensen, M. C., Satyamurthy, N., Budhiraja, S., Paik, D., Czernin, J., et al. (2009). Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nature Clinical Practice Oncology, 6(1), 53\u201358. https:\/\/doi.org\/10.1038\/ncponc1278","journal-title":"Nature Clinical Practice Oncology"},{"key":"10214_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag2196","author":"KV Keu","year":"2017","unstructured":"Keu, K. V., Witney, T. H., Yaghoubi, S., Rosenberg, J., Kurien, A., Magnusson, R., et al. (2017). Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.aag2196","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10214_CR119","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018). Improving immune-vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 18(3), 195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145","journal-title":"Nature Reviews Immunology"},{"key":"10214_CR120","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis, E., Irving, M., & Coukos, G. (2015). Targeting the tumor vasculature to enhance T cell activity. Current Opinion in Immunology, 33, 55\u201363. https:\/\/doi.org\/10.1016\/j.coi.2015.01.011","journal-title":"Current Opinion in Immunology"},{"issue":"6801","key":"10214_CR121","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407(6801), 249\u2013257. https:\/\/doi.org\/10.1038\/35025220","journal-title":"Nature"},{"issue":"6398","key":"10214_CR122","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/359843a0","volume":"359","author":"D Shweiki","year":"1992","unstructured":"Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359(6398), 843\u2013845. https:\/\/doi.org\/10.1038\/359843a0","journal-title":"Nature"},{"issue":"2","key":"10214_CR123","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1172\/jci114759","volume":"86","author":"S Kourembanas","year":"1990","unstructured":"Kourembanas, S., Hannan, R. L., & Faller, D. V. (1990). Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. The Journal of Clinical Investigation, 86(2), 670\u2013674. https:\/\/doi.org\/10.1172\/jci114759","journal-title":"The Journal of Clinical Investigation"},{"issue":"5706","key":"10214_CR124","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain, R. K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307(5706), 58\u201362. https:\/\/doi.org\/10.1126\/science.1104819","journal-title":"Science"},{"issue":"5","key":"10214_CR125","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain, R. K. (2014). Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell, 26(5), 605\u2013622. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.006","journal-title":"Cancer Cell"},{"issue":"1","key":"10214_CR126","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., et al. (2008). Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Medicine, 14(1), 28\u201336. https:\/\/doi.org\/10.1038\/nm1699","journal-title":"Nature Medicine"},{"issue":"15","key":"10214_CR127","first-page":"4265","volume":"52","author":"NZ Wu","year":"1992","unstructured":"Wu, N. Z., Klitzman, B., Dodge, R., & Dewhirst, M. W. (1992). Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Research, 52(15), 4265\u20134268.","journal-title":"Cancer Research"},{"issue":"3","key":"10214_CR128","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/73163","volume":"6","author":"M Granovsky","year":"2000","unstructured":"Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R., & Dennis, J. W. (2000). Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Medicine, 6(3), 306\u2013312. https:\/\/doi.org\/10.1038\/73163","journal-title":"Nature Medicine"},{"issue":"43","key":"10214_CR129","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., et al. (2012). Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences USA, 109(43), 17561\u201317566. https:\/\/doi.org\/10.1073\/pnas.1215397109","journal-title":"Proceedings of the National Academy of Sciences USA"},{"issue":"5","key":"10214_CR130","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018). Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nature Reviews. Clinical Oncology, 15(5), 325\u2013340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"11","key":"10214_CR131","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/jci43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., et al. (2010). Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation, 120(11), 3953\u20133968. https:\/\/doi.org\/10.1172\/jci43490","journal-title":"The Journal of Clinical Investigation"},{"key":"10214_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","author":"X Dong","year":"2023","unstructured":"Dong, X., Ren, J., Amoozgar, Z., Lee, S., Datta, M., Roberge, S., et al. (2023). Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005583","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"4","key":"10214_CR133","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/path.1700640403","volume":"64","author":"OA Trowell","year":"1952","unstructured":"Trowell, O. A. (1952). The sensitivity of lymphocytes to ionising radiation. The Journal of Pathology and Bacteriology, 64(4), 687\u2013704. https:\/\/doi.org\/10.1002\/path.1700640403","journal-title":"The Journal of Pathology and Bacteriology"},{"issue":"6","key":"10214_CR134","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/095530099140113","volume":"75","author":"H Louagie","year":"1999","unstructured":"Louagie, H., Van Eijkeren, M., Philippe, J., Thierens, H., & de Ridder, L. (1999). Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. International Journal of Radiation Biology, 75(6), 767\u2013771. https:\/\/doi.org\/10.1080\/095530099140113","journal-title":"International Journal of Radiation Biology"},{"issue":"7","key":"10214_CR135","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., et al. (2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Research, 71(7), 2488\u20132496. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2820","journal-title":"Cancer Research"},{"issue":"10","key":"10214_CR136","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., et al. (2012). Immunologic correlates of the abscopal effect in a patient with melanoma. New England Journal of Medicine, 366(10), 925\u2013931. https:\/\/doi.org\/10.1056\/NEJMoa1112824","journal-title":"New England Journal of Medicine"},{"key":"10214_CR137","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102611118","author":"DM Lussier","year":"2021","unstructured":"Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., et al. (2021). Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences USA. https:\/\/doi.org\/10.1073\/pnas.2102611118","journal-title":"Proceedings of the National Academy of Sciences USA"},{"issue":"1","key":"10214_CR138","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","volume":"115","author":"KE Salerno","year":"2023","unstructured":"Salerno, K. E., Roy, S., Ribaudo, C., Fisher, T., Patel, R. B., Mena, E., et al. (2023). A primer on radiopharmaceutical therapy. International Journal of Radiation Oncology Biology Physics, 115(1), 48\u201359. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.08.010","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"10214_CR139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3631","author":"RB Patel","year":"2021","unstructured":"Patel, R. B., Hernandez, R., Carlson, P., Grudzinski, J., Bates, A. M., Jagodinsky, J. C., et al. (2021). Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.abb3631","journal-title":"Science Translational Medicine"},{"issue":"620","key":"10214_CR140","doi-asserted-by":"publisher","first-page":"0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B., Zebley, C. C., Petersen, C. T., Fan, Y., Anido, A. A., Yi, Z., et al. (2021). Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Science Translational Medicine, 13(620), 0272. https:\/\/doi.org\/10.1126\/scitranslmed.abh0272","journal-title":"Science Translational Medicine"},{"issue":"32","key":"10214_CR141","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., et al. (2014). Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proceedings of the National Academy of Sciences, 111(32), 11774\u201311779. https:\/\/doi.org\/10.1073\/pnas.1410626111","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7798","key":"10214_CR142","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., et al. (2020). Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature, 579(7798), 284\u2013290. https:\/\/doi.org\/10.1038\/s41586-020-2054-x","journal-title":"Nature"},{"issue":"8","key":"10214_CR143","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402x.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., et al. (2018). TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology, 7(8), e1466769. https:\/\/doi.org\/10.1080\/2162402x.2018.1466769","journal-title":"Oncoimmunology"},{"issue":"3","key":"10214_CR144","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L., Xu, X., Chitre, A. S., Au-Yeung, A., Takahashi, C., O\u2019Gorman, W. E., et al. (2022). Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity, 55(3), 512-526.e519. https:\/\/doi.org\/10.1016\/j.immuni.2022.02.005","journal-title":"Immunity"},{"issue":"1","key":"10214_CR145","doi-asserted-by":"publisher","first-page":"2265703","DOI":"10.1080\/2162402X.2023.2265703","volume":"12","author":"J Zhao","year":"2023","unstructured":"Zhao, J., Dong, J., Deng, C., Zhang, Q., Sun, S., Li, H., et al. (2023). Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor. Oncoimmunology, 12(1), 2265703. https:\/\/doi.org\/10.1080\/2162402X.2023.2265703","journal-title":"Oncoimmunology"},{"key":"10214_CR146","doi-asserted-by":"publisher","first-page":"115740","DOI":"10.1016\/j.biopha.2023.115740","volume":"168","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Farooq, M. A., Ajmal, I., He, C., Gao, Y., Guo, D., et al. (2023). Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Biomedicine & Pharmacotherapy, 168, 115740. https:\/\/doi.org\/10.1016\/j.biopha.2023.115740","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"4","key":"10214_CR147","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018). IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nature Biotechnology, 36(4), 346\u2013351. https:\/\/doi.org\/10.1038\/nbt.4086","journal-title":"Nature Biotechnology"},{"issue":"20","key":"10214_CR148","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.Ccr-20-0777","volume":"26","author":"H Luo","year":"2020","unstructured":"Luo, H., Su, J., Sun, R., Sun, Y., Wang, Y., Dong, Y., et al. (2020). Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clinical Cancer Research, 26(20), 5494\u20135505. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0777","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10214_CR149","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.scib.2020.12.027","volume":"66","author":"L Jin","year":"2021","unstructured":"Jin, L., Cao, L., Zhu, Y., Cao, J., Li, X., Zhou, J., et al. (2021). Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C-C motif chemokine receptor 6. Science Bulletin, 66(8), 803\u2013812. https:\/\/doi.org\/10.1016\/j.scib.2020.12.027","journal-title":"Science Bulletin"},{"issue":"14","key":"10214_CR150","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.Ccr-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K., Carpenito, C., Sun, J., Wang, L. C., Kapoor, V., Predina, J., et al. (2011). Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clinical Cancer Research, 17(14), 4719\u20134730. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0351","journal-title":"Clinical Cancer Research"},{"key":"10214_CR151","doi-asserted-by":"publisher","first-page":"628906","DOI":"10.3389\/fimmu.2021.628906","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Wang, J., Yang, X., Yang, J., Lu, P., Zhao, L., et al. (2021). Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model. Frontiers in Immunology, 12, 628906. https:\/\/doi.org\/10.3389\/fimmu.2021.628906","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10214_CR152","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., et al. (2010). Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. Journal of Immunotherapy, 33(8), 780\u2013788. https:\/\/doi.org\/10.1097\/CJI.0b013e3181ee6675","journal-title":"Journal of Immunotherapy"},{"key":"10214_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020197","author":"JA Meier","year":"2022","unstructured":"Meier, J. A., Savoldo, B., & Grover, N. S. (2022). The emerging role of CAR T cell therapy in relapsed\/refractory Hodgkin lymphoma. Journal of Personalized Medicine. https:\/\/doi.org\/10.3390\/jpm12020197","journal-title":"Journal of Personalized Medicine"},{"key":"10214_CR154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1872","author":"R Nguyen","year":"2023","unstructured":"Nguyen, R., Doubrovina, E., Mousset, C. M., Jin, B. Y., Okada, R., Zhang, X., et al. (2023). Cooperative armoring of CAR and TCR T-cells by T cell-restricted IL-15 and IL-21 universally enhances solid tumor efficacy. Clinical Cancer Research. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1872","journal-title":"Clinical Cancer Research"},{"key":"10214_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000210","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Davies, J. S., Serna, C., Yu, Z., Restifo, N. P., Rosenberg, S. A., et al. (2020). Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. Journal for ImmunoTherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000210","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"13","key":"10214_CR156","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., et al. (2017). Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Reports, 20(13), 3025\u20133033. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.002","journal-title":"Cell Reports"},{"key":"10214_CR157","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","author":"JE Jaspers","year":"2023","unstructured":"Jaspers, J. E., Khan, J. F., Godfrey, W. D., Lopez, A. V., Ciampricotti, M., Rudin, C. M., et al. (2023). IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. The Journal of Clinical Investigation. https:\/\/doi.org\/10.1172\/JCI166028","journal-title":"The Journal of Clinical Investigation"},{"issue":"8","key":"10214_CR158","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","volume":"184","author":"S Kaczanowska","year":"2021","unstructured":"Kaczanowska, S., Beury, D. W., Gopalan, V., Tycko, A. K., Qin, H., Clements, M. E., et al. (2021). Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell, 184(8), 2033\u20132052. https:\/\/doi.org\/10.1016\/j.cell.2021.02.048. e2021.","journal-title":"Cell"},{"issue":"1","key":"10214_CR159","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi, G., Liuzzi, A. R., Hotblack, A., De Feo, D., Nunez, N., Stowe, C. L., et al. (2021). Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nature Communications, 12(1), 444. https:\/\/doi.org\/10.1038\/s41467-020-20599-x","journal-title":"Nature Communications"},{"issue":"17","key":"10214_CR160","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011). IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Research, 71(17), 5697\u20135706. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0103","journal-title":"Cancer Research"},{"issue":"1","key":"10214_CR161","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41467-023-37646-y","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang, Y., Yang, H., Alcaina, Y., Puc, J., Birt, A., Vedvyas, Y., et al. (2023). Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models. Nature Communications, 14(1), 2068. https:\/\/doi.org\/10.1038\/s41467-023-37646-y","journal-title":"Nature Communications"},{"issue":"4","key":"10214_CR162","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., et al. (2011). Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Molecular Therapy, 19(4), 751\u2013759. https:\/\/doi.org\/10.1038\/mt.2010.313","journal-title":"Molecular Therapy"},{"key":"10214_CR163","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trsl.2019.02.006","volume":"209","author":"C Chandler","year":"2019","unstructured":"Chandler, C., Liu, T., Buckanovich, R., & Coffman, L. G. (2019). The double edge sword of fibrosis in cancer. Translational Research, 209, 55\u201367. https:\/\/doi.org\/10.1016\/j.trsl.2019.02.006","journal-title":"Translational Research"},{"issue":"5","key":"10214_CR164","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.neo.2015.04.004","volume":"17","author":"LT McDonald","year":"2015","unstructured":"McDonald, L. T., Russell, D. L., Kelly, R. R., Xiong, Y., Motamarry, A., Patel, R. K., et al. (2015). Hematopoietic stem cell\u2013derived cancer\u2013associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia, 17(5), 434\u2013448. https:\/\/doi.org\/10.1016\/j.neo.2015.04.004","journal-title":"Neoplasia"},{"issue":"1","key":"10214_CR165","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1038\/ncomms10204","volume":"6","author":"J Albrengues","year":"2015","unstructured":"Albrengues, J., Bertero, T., Grasset, E., Bonan, S., Maiel, M., Bourget, I., et al. (2015). Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nature Communications, 6(1), 10204. https:\/\/doi.org\/10.1038\/ncomms10204","journal-title":"Nature Communications"},{"issue":"2","key":"10214_CR166","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante, M., Tu, S. P., Tomita, H., Gonda, T., Wang, S. S. W., Takashi, S., et al. (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 19(2), 257\u2013272. https:\/\/doi.org\/10.1016\/j.ccr.2011.01.020","journal-title":"Cancer Cell"},{"key":"10214_CR167","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong, M., Talluri, S., & Chen, Y. Y. (2023). Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Current Opinion in Biotechnology, 84, 103020. https:\/\/doi.org\/10.1016\/j.copbio.2023.103020","journal-title":"Current Opinion in Biotechnology"},{"key":"10214_CR168","doi-asserted-by":"publisher","first-page":"637675","DOI":"10.3389\/fcell.2021.637675","volume":"9","author":"Y Ni","year":"2021","unstructured":"Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., et al. (2021). The role of tumor-stroma interactions in drug resistance within tumor microenvironment. Front Cell Dev Biol, 9, 637675. https:\/\/doi.org\/10.3389\/fcell.2021.637675","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"10214_CR169","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","volume":"14","author":"E Ostermann","year":"2008","unstructured":"Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C., et al. (2008). Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clinical Cancer Research, 14(14), 4584\u20134592. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5211","journal-title":"Clinical Cancer Research"},{"issue":"14","key":"10214_CR170","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","volume":"75","author":"A Lo","year":"2015","unstructured":"Lo, A., Wang, L. S., Scholler, J., Monslow, J., Avery, D., Newick, K., et al. (2015). Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Research, 75(14), 2800\u20132810. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3041","journal-title":"Cancer Research"},{"issue":"2","key":"10214_CR171","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., et al. (2014). Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunology Research, 2(2), 154\u2013166. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0027","journal-title":"Cancer Immunology Research"},{"issue":"4801","key":"10214_CR172","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.2953071","volume":"236","author":"JW Dennis","year":"1987","unstructured":"Dennis, J. W., Lafert\u00e9, S., Waghorne, C., Breitman, M. L., & Kerbel, R. S. (1987). Beta 1\u20136 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science, 236(4801), 582\u2013585. https:\/\/doi.org\/10.1126\/science.2953071","journal-title":"Science"},{"issue":"628","key":"10214_CR173","doi-asserted-by":"publisher","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","volume":"14","author":"B Greco","year":"2022","unstructured":"Greco, B., Malacarne, V., De Girardi, F., Scotti, G. M., Manfredi, F., Angelino, E., et al. (2022). Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Science Translational Medicine, 14(628), eabg3072. https:\/\/doi.org\/10.1126\/scitranslmed.abg3072","journal-title":"Science Translational Medicine"},{"key":"10214_CR174","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024). CAR-T cell manufacturing: Major process parameters and next-generation strategies. Journal of Experimental Medicine. https:\/\/doi.org\/10.1084\/jem.20230903","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"10214_CR175","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael, J., Fowler, J., & Shah, N. (2022). Chimeric antigen receptor T-cell therapies: Barriers and solutions to access. JCO Oncology Practice, 18(12), 800\u2013807. https:\/\/doi.org\/10.1200\/OP.22.00315","journal-title":"JCO Oncology Practice"},{"issue":"8","key":"10214_CR176","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020). In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Molecular Therapy, 28(8), 1783\u20131794. https:\/\/doi.org\/10.1016\/j.ymthe.2020.05.005","journal-title":"Molecular Therapy"},{"issue":"22","key":"10214_CR177","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/bloodadvances.2020002229","volume":"4","author":"AM Frank","year":"2020","unstructured":"Frank, A. M., Braun, A. H., Scheib, L., Agarwal, S., Schneider, I. C., Fusil, F., et al. (2020). Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Advances, 4(22), 5702\u20135715. https:\/\/doi.org\/10.1182\/bloodadvances.2020002229","journal-title":"Blood Advances"},{"issue":"6576","key":"10214_CR178","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G., Tombacz, I., Yadegari, A., Mendez Fernandez, P. O., Shewale, S. V., Li, L., et al. (2022). CAR T cells produced in vivo to treat cardiac injury. Science, 375(6576), 91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science"},{"issue":"8","key":"10214_CR179","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., et al. (2017). In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology, 12(8), 813\u2013820. https:\/\/doi.org\/10.1038\/nnano.2017.57","journal-title":"Nature Nanotechnology"},{"key":"10214_CR180","doi-asserted-by":"publisher","first-page":"122580","DOI":"10.1016\/j.biomaterials.2024.122580","volume":"308","author":"S Pandit","year":"2024","unstructured":"Pandit, S., Agarwalla, P., Song, F., Jansson, A., Dotti, G., & Brudno, Y. (2024). Implantable CAR T cell factories enhance solid tumor treatment. Biomaterials, 308, 122580. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122580","journal-title":"Biomaterials"},{"issue":"7","key":"10214_CR181","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., et al. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: First-in-human clinical study. Blood Cancer Journal, 12(7), 104. https:\/\/doi.org\/10.1038\/s41408-022-00694-6","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"10214_CR182","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S., Durgin, J. S., Nunez-Cruz, S., Patel, J., Leferovich, J., Pinzone, M., et al. (2022). Rapid manufacturing of non-activated potent CAR T cells. Nature Biomedical Engineering, 6(2), 118\u2013128. https:\/\/doi.org\/10.1038\/s41551-021-00842-6","journal-title":"Nature Biomedical Engineering"},{"issue":"Supplement 1","key":"10214_CR183","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2022-162520","volume":"140","author":"P Barba","year":"2022","unstructured":"Barba, P., Kwon, M., Briones, J., Jaeger, U., Bachy, E., Blaise, D., et al. (2022). YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed\/refractory diffuse large B-cell lymphoma: Phase I study update. Blood, 140(Supplement 1), 1056\u20131059. https:\/\/doi.org\/10.1182\/blood-2022-162520","journal-title":"Blood"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10214-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10214-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10214-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:12:33Z","timestamp":1731345153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10214-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":183,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10214"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10214-6","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"R.N. filed a patent (WO2023158986A1) for GPC2-CARs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}